Surveillance of:
• Adenomatous polyps: 13.5 percent
• Colorectal cancer: 2 percent
• Ulcerative colitis: 0.9 percent
• Crohn’s disease: 0.6 percent
• Established Crohn’s disease: 0.2 percent
• Established ulcerative colitis: 0.2 percent
Screening:
• Routine risk only: 21.6 percent
• Family history of colorectal cancer: 12.1 percent
• Family history of polyps: 2.8 percent
Symptoms:
• Bleeding: 29.7 percent
• Irritable bowel syndrome: 18.2 percent
• Hematochezia: 17.9 percent
• Abdominal pain/bloating: 9.1 percent
• Diarrhea: 7.6 percent
• Positive fecal occult blood test: 7.2 percent
• Change in bowel habits: 7.1 percent
• Anemia: 5.7 percent
• Constipation: 5.4 percent
• Weight loss: 1.6 percent
• Melena: 0.7 percent
• Iron deficiency without anemia: 0.3 percent
Follow-up diagnosis of:
• Polyp found in flexible sigmoidoscopy: 1.5 percent
• Abnormal study: 1 percent
• History of non-GI cancer: 0.8 percent
• Suspected IBS: 0.5 percent
• Polyp found in barium enema: 0.2 percent
• Polyp found in previous colonoscopy: 0.2 percent
Other:
• 6.5 percent
More Articles on Gastroenterology:
Screening Efforts Show Results, Colorectal Cancer Rates Drop 30%
AGA Launches Observational Research Device Registries
6 Gastroenterologists on Improving Efficiency in the Field
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
